Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Medical Physics|July 3, 2015
A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patientsScott P Robertson, Harry Quon, Ana P Kiess, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of lifeS Z Hazell, W Fu, C Hu, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|April 13, 2013
The effect of anterior proton beams in the setting of a prostate-rectum spacerJohn P Christodouleas, Shikui Tang, Robert C Susil, et al.
BMC Cancer|April 21, 2020
Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impactSarah Z Hazell, Nicholas Mai, Wei Fu, et al.
Practical Radiation Oncology|March 29, 2014
Developing a national radiation oncology registry: From acorns to oaksJatinder R Palta, Jason A Efstathiou, Justin E Bekelman, et al.
Journal of the American College of Radiology : JACR|February 11, 2019
Patterns of Incident Reporting Across Clinical Sites in a Regionally Expanding Academic Radiation Oncology DepartmentByung-Han Rhieu, Stephanie A Terezakis, Stephen Greco, et al.
Advances in Radiation Oncology|April 3, 2023
Improving Quality Metrics in Radiation Oncology: Implementation of Pretreatment Peer Review for Stereotactic Body Radiation Therapy in Patients with Thoracic CancerCarmen Kut, Leslie Chang, Russell K Hales, et al.
JCO Oncology Practice|February 8, 2021
Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort StudyCole Friedes, Sarah Z Hazell, Wei Fu, et al.
Practical Radiation Oncology|June 29, 2019
Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung CancerSarah Z Hazell, Russell K Hales, William T Hrinivich, et al.
Anti-Cancer Drug Design|January 5, 2002
A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activityE Wood, R M Crosby, S Dickerson, et al.
Pageof 8